Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 38, Issue 11, Pages 992-1005Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2017.08.003
Keywords
-
Categories
Funding
- Russian Science Foundation [14-50-00069]
- Russian Foundation for Basic Research [16-04-00851]
- Southwest University
- ZENEREI Center
- St. Petersburg State University
- Ural Federal University
- Guangdong Ocean University
Ask authors/readers for more resources
Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials, suggesting these compounds as promising treatments for addiction, depression, anxiety, and other conditions. However, many questions regarding the mechanisms of action, safety, and efficacy of psychedelics remain. Here, we summarize recent preclinical and clinical data in this field, discuss their pharmacological mechanisms of action, and outline critical areas for future studies of psychedelic drugs, with the goal of maximizing the potential benefits of translational psychedelic biomedicine to patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available